ClinicalTrials.gg
RecruitingNCT03680794Updated Apr 30, 2026

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

An interventional study of sampling of ophthalmic liquid in Diabetic Retinopathy and Retinal Vein Occlusion, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by CHU de Reims · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Diabetic Retinopathy with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Diabetic Retinopathy · France.

Planned enrollment
11th of 19
120 · median 135
Started
2018
with 2 others
No phase
11 of 30
3 open now
Registered
18th of 30
by date
Lead sponsor
4 of 30
CHU de Reims

Among the 30 studies in Diabetic Retinopathy with a site in France, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2018, is one of 11 with no phase, and was the 18th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

5 of the 30 studies in Diabetic Retinopathy with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Diabetic Retinopathy with a site in France, or all of them as a file.
02

Study summary

CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic therapies that target the VEGF/VEGF-R pathway. A soluble form of CD160, sCD160, has been found to be highly expressed in the vitreous and the sera of patients with severe diabetic retinopathies, and can now be dosed with help of an ELISA test.

The investigators aim to evaluate the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations in the vitreous, the aqueous humour and the serum.

Read the detailed description

120 patients enrolled for ophthalmic surgery (cataract or posterior segment surgery (epiretinal membrane, macular hole, vitrectomy)) will be recruited in the Department of Ophthalmology, Robert Debré Hospital, Reims, France.

Each patient will benefit a complete ophthalmologic examination, and either an aqueous sampling (cataract) or a vitreous sampling (posterior segment) along with a serum sampling at the beginning of the surgery. ELISA test will be performed on vitreous or aqueous samples in triplicates. Luminex will be performed on vitreous samples in order to determine the concentrations of several ischemia biomarkers (VEGF, PlGF, Platelet-derived growth factor (PDGF-B), SDF-1, Angpt2, InterIeukin IL-6, IL-8, CD105, Monocyte chemoattractant protein 1 (MCP-1), IL-10, interferon-inducible protein-10 ( IP-10), IL-1B and CD106, RAGE).

Primary objective is:

- Evaluation of the association between ischaemic retinopathies (patients with or without) and sCD160 concentrations of the vitreous or the aqueous humours.

Secondary objectives are:

  • Evaluation of the association between diabetic retinopathies (patients with or without) and sCD160 concentrations of the vitreous, the aqueous humours and the sera.
  • Evaluation of the association between several vitreous biomarkers of ischaemia and sCD160 concentrations of the vitreous and the sera.
  • Evaluation of the association between sCD160 concentrations in the vitreous and the sera.
  • Evaluation of the association between sCD160 concentration in the aqueous humours and the sera.
03

Conditions studied

  • Diabetic Retinopathy
  • Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

inclusion criteria :

  • over 18 years old
  • with social security affiliation
  • willing to participate this study non-inclusion criteria :
  • any prior (3 months) or concomitant treatment with anti-VEGF therapy, , or agents
  • any history of previous vitreoretinal surgery, ocular tumor, severe ocular trauma, severe intraocular, periocular infection, inflammation, or radiation
  • any serious allergy to the fluorescein sodium for injection in angiography
  • any history of previous systemic anti-VEGF treatment
  • any history of inflammatory or auto-immune disease
  • any active extraocular inflammation or infection in the last 4 weeks before surgery exclusion criteria :
  • Patients with C-reactive protein CRP > 10mg/mL (serum sampling during surgery)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Patients with ophthalmic surgery

    Other: sampling of ophthalmic liquid

Interventions

  • Othersampling of ophthalmic liquid

    aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery

06

What researchers measure

Primary outcomes

  1. sCD160 concentration in the vitreous humor

    ELISA test

    Time frame: Day 0

  2. sCD160 concentration in the aqueous humor

    ELISA test

    Time frame: Day 0

Secondary outcomes

  1. sCD160 concentration in the serum

    ELISA test

    Time frame: Day 0

  2. Diabetic retinopathy severity

    Angiography

    Time frame: Day 0

  3. Vascular endothelial growth factor (VEGF)

    LUMINEX test

    Time frame: Day 0

  4. Placenta Growth Factor-1(PlGF)

    LUMINEX test

    Time frame: Day 0

  5. Stromal cell-derived factor 1 (SDF-1)

    LUMINEX test

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2018 (actual). Primary completion is estimated for Dec 2027, 114 months after the start.

Of 111 non-industry interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 114 months is above that.

Counting every sponsor, half of 126 studies reached it within 29 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
Sep 21, 2018
StartActual
Jun 27, 2018
Primary completionEst.
Dec 27, 2027
CompletionEst.
Feb 27, 2028
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03680794
Lead sponsor
CHU de Reims
Responsible party
Sponsor
First posted
Sep 21, 2018
Start date
Jun 27, 2018
Primary completion
Dec 27, 2027 (estimated)
Completion
Feb 27, 2028 (estimated)
Last update
Apr 30, 2026

Study contacts

Carl ARNDT
Contact
carndt@chu-reims.fr
326787090 ext. 0033

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion